Recent News

Symposium addresses an age-old question about older cancer patients

Symposium addresses an age-old question about older cancer patients

The University of North Carolina Lineberger Comprehensive Cancer Center Geriatric Research Symposium, held Dec. 2, featured seven presentations and panel discussions focused on muscle mass, aging and patient function.

Symposium addresses an age-old question about older cancer patients - Read More…

UNC Lineberger researchers present findings at San Antonio Breast Cancer Symposium

UNC Lineberger researchers present findings at San Antonio Breast Cancer Symposium

UNC Lineberger breast cancer faculty members presented their research findings at the 2016 San Antonio Breast Cancer Symposium Dec. 6-10. The meeting drew more than 7,000 cancer caregivers and scientists from around the world, who attended talks and presentations on the latest developments in breast cancer care and research.

UNC Lineberger researchers present findings at San Antonio Breast Cancer Symposium - Read More…

For invasive breast cancer, researchers identify biomarkers of treatment response

For invasive breast cancer, researchers identify biomarkers of treatment response

UNC Lineberger researchers reported at the San Antonio Breast Cancer Symposium they have identified biomarkers they believe can be used as part of a larger model to predict how patients with HER2-positive operative breast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemotherapy.

For invasive breast cancer, researchers identify biomarkers of treatment response - Read More…

Brain metastasis persists despite improved targeted treatment for HER2 breast cancer

Brain metastasis persists despite improved targeted treatment for HER2 breast cancer

At this year's San Antonio Breast Cancer Symposium, UNC Lineberger researchers and collaborators shared the outcomes of their investigation into the incidence of brain metastasis after a series of drugs were approved to treat HER2-positive metastatic breast cancer, starting with trastuzumab, also known as Herceptin, in the United States in 1998.

Brain metastasis persists despite improved targeted treatment for HER2 breast cancer - Read More…